- This Week in Biopharma Deals, by biodealroom
- Posts
- Slicing off a piece of aficamten for Bayer
Slicing off a piece of aficamten for Bayer
Week 47 Deals (2024)
Deal of the Week: Cytokinetics & Bayer Licensing Collaboration for Aficamten in Japan [GlobeNewswire]
Bayer secures exclusive rights to commercialize aficamten in Japan, expanding its cardiovascular portfolio
Structure: Exclusive licensing agreement
Date Announced: November 19, 2024
Total Deal Value: Not disclosed
Phase: Phase 3
Therapeutic Focus: Cardiomyopathy (heart failure)
Strategic Impact: This deal strengthens Bayer’s cardiovascular pipeline and positions aficamten for success in the Japanese market.
Notable Deals
Steritas & Argenx Collaboration on Steroid-Sparing Therapeutics [BusinessWire]
Argenx and Steritas team up to develop steroid-sparing options for autoimmune diseases
Structure: Research collaboration agreement
Date Announced: November 19, 2024
Total Deal Value: Not disclosed
Phase: Preclinical
Therapeutic Focus: Autoimmune diseases
Flagship Pioneering & Pfizer Expand Strategic Partnership [PRNewswire]
Flagship companies Ampersand Biomedicines and Montai Therapeutics join Pfizer’s innovation ecosystem
Structure: Multi-company partnership agreements under Pfizer’s strategic collaboration with Flagship Pioneering
Date Announced: November 20, 2024
Total Deal Value: Not disclosed
Phase: Discovery
Therapeutic Focus: Precision medicine and novel therapeutic modalities
23andMe & Mirador Therapeutics Research Collaboration [GlobeNewswire]
Advancing precision medicines for immunology and inflammation through strategic research collaboration
Structure: Strategic research collaboration agreement
Date Announced: November 20, 2024
Total Deal Value: Not disclosed
Phase: Discovery
Therapeutic Focus: Immunology and inflammation
Kura Oncology & Kyowa Kirin Global Collaboration on Ziftomenib [GlobeNewswire]
Developing and commercializing Ziftomenib for acute leukemias globally
Structure: Global strategic collaboration agreement
Date Announced: November 20, 2024
Total Deal Value: Not disclosed (likely includes milestone payments and royalties)
Phase: Phase 2/3
Therapeutic Focus: Acute myeloid leukemia
Zai Lab & Pfizer Strategic Collaboration on XACDURO® [BusinessWire]
Commercialization partnership for novel antibacterial drug in Asia-Pacific markets
Structure: Strategic collaboration agreement
Date Announced: November 21, 2024
Total Deal Value: Not disclosed
Phase: Marketed
Therapeutic Focus: Antibacterial therapy
Vilya & University of Washington Licensing Agreement [GlobeNewswire]
Exclusive license for RFdiffusion-based generative model to design macrocyclic peptides
Structure: Exclusive licensing agreement for computational drug design technology
Date Announced: November 21, 2024
Total Deal Value: Not disclosed
Phase: Discovery